Research cuts threaten U.S. competitiveness, drug industry execs say

03/6/2013 | Forbes

Public funding of agencies that support scientific and biomedical research pays significant dividends and should be restored immediately, write former Genentech chief scientific officer Marc Tessier-Lavigne, Regeneron Pharmaceuticals chairman P. Roy Vagelos and former NIH Director and Sanofi R&D president Elias Zerhouni. Great strides have been made in cardiovascular and HIV/AIDS research thanks to NIH funding, but Alzheimer's disease, diabetes and other chronic diseases threaten to break the nation's bank in the absence of investments in research, they write. Even before sequestration, steadily eroding funds squeezed research and sent many U.S. scientists abroad, harming U.S. competitiveness, they write.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC